Last reviewed · How we verify
Madopar® 125
At a glance
| Generic name | Madopar® 125 |
|---|---|
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics (PHASE1)
- Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide (PHASE1)
- Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg) (PHASE1)
- Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |